Joe Jimenez joined Novartis as division head of Consumer Health. A few months later, he was asked to run the pharmaceutical division. Shortly after his promotion to CEO, Novartis was the first company to pursue a CAR T therapy. Today, Jimenez marvels at the innovation taking place in the industry, and believes cell and gene therapies will drive future development.
HIV drug developers have a whole new set of challenges, including making the regimens simpler better tolerated. In addition, since today’s patients can access these medicines through pharmacies, they no longer have the incentive to take part in clinical studies.
Changing the culture within a large company can be a difficult endeavour. That is certainly true when trying to make your company and your clinical trials more patient centric. Janssen is one of many pharma companies attempting to get the voice of patients more incorporated into product development and trial designs.
According to Dr. Judith Absalon, senior medical director in vaccines clinical research and development at Pfizer, vaccinating pregnant women goes back several decades. Still, we seem to be amid a new frontier in vaccine innovation. Pfizer is working on an investigational vaccine designed to protect unborn infants against GBS infection.
Virtual trials are growing in acceptance. The patient-centric aspect of these trials makes them easier to recruit and retain patients and accelerate timelines, while also providing patient data to researchers in real time. But will virtual trials also mean the end of CROs?
While many other oncology companies are focused on the development of targeted immuno-oncology therapies, Rafael Pharmaceuticals is working on a cancer metabolism drug that has the potential to revolutionize cancer treatment. Its primary objective is to produce anti-cancer agents that have minimal toxic effects on normal cells and tissues.
Antony Loebel, president and CEO for Sunovion Pharmaceuticals, will be a featured speaker at the upcoming 2019 CNS Summit. In this Q&A, Loebel discusses CNS innovation, balancing the needs of clinical stakeholders, and the biggest changes we can expect over the next 10 years.
A 2017 report published by Deloitte concluded that much of the current stagnation in drug discovery is due to the industry’s limited understanding of the fundamental molecular mechanisms of disease. Dr. Niven Narain, co-founder, president, and CEO of BERG believes getting a handle on those mechanisms is vital to producing more effective therapies in a shorter amount of time.
Ian M. Marks, VP R&D Innovation, GSK Consumer Healthcare, will be a featured speaker at the upcoming 2019 CNS Summit. In this Q&A, Marks discusses AI, machine learning, virtual trials, and how innovation will help pharma move from “making us better” to “keeping us well.”
Bella Sessoms has spent most of her career negotiating sponsor-CRO budgets and contracts. In her current position as director, contracts and outsourcing at Astellas Pharma, she leads a team of outsourcing managers who prepare vendor and site contracts. Below are the six efforts Sessoms believes you must undertake to make your contracting endeavor a success.
